Literatura académica sobre el tema "Prostate – Hypertrophy"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Prostate – Hypertrophy".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Prostate – Hypertrophy"
Viennois, Emilie, Teresa Esposito, Julie Dufour, Aurélien Pommier, Stephane Fabre, Jean-Louis Kemeny, Laurent Guy, Laurent Morel, Jean-Marc Lobaccaro y Silvère Baron. "Lxrα Regulates the Androgen Response in Prostate Epithelium". Endocrinology 153, n.º 7 (30 de abril de 2012): 3211–23. http://dx.doi.org/10.1210/en.2011-1996.
Texto completoG., Diamantis y Tode V. "Consideration of Drug Therapy in Benign Prostatic Hypertrophy". ARS Medica Tomitana 20, n.º 3 (31 de enero de 2015): 129–34. http://dx.doi.org/10.2478/arsm-2014-0023.
Texto completoLi, Peng-Long, Hui Liu, Guo-Peng Chen, Ling Li, Hong-Jie Shi, Hong-Yu Nie, Zhen Liu et al. "STEAP3 (Six-Transmembrane Epithelial Antigen of Prostate 3) Inhibits Pathological Cardiac Hypertrophy". Hypertension 76, n.º 4 (octubre de 2020): 1219–30. http://dx.doi.org/10.1161/hypertensionaha.120.14752.
Texto completoMerendino, Rosaria Alba, Francesco Salvo, Antonella Saija, Giuseppe Di Pasquale, Antonio Tomaino, Paola Lucia Minciullo, Giuseppe Fraccica y Sebastiano Gangemi. "Malondialdehyde in benign prostate hypertrophy: a useful marker?" Mediators of Inflammation 12, n.º 2 (2003): 127–28. http://dx.doi.org/10.1080/0962935031000097745.
Texto completoNath, Chandan Kumar, Bhupen Barman, Pranjal Phukan, Stephen L. Sailo, Biswajit Dey, Indrajit Nath y Purnima Rajkhowa. "Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma". Journal of Laboratory Physicians 12, n.º 01 (marzo de 2020): 44–48. http://dx.doi.org/10.1055/s-0040-1714195.
Texto completoPanarisi, S., M. Barbera, C. Cammarata, Q. Paola, G. Solazzo, F. Curto y G. Curto. "Mini-invasive treatment of BPH with TUIP". Urologia Journal 65, n.º 1 (febrero de 1998): 137–39. http://dx.doi.org/10.1177/039156039806500135.
Texto completoGnana, Bhushan Kumar y Sanjeeva Rao Matlapudi. "A comparative clinical evaluation of outcome of medical and surgical management of symptoms due to benign prostatic hyperplasia". International Surgery Journal 7, n.º 9 (27 de agosto de 2020): 3032. http://dx.doi.org/10.18203/2349-2902.isj20203789.
Texto completoZambolin, T., A. Cozzoli, G. Cancarini, G. P. Da Pozzo, C. Simeone, M. Scanzi, L. Tralce, F. Pagani y S. Cosciani-Cunico. "Correlation between benign prostatic hypertrophy (BPH) and prostatic antigen (PSA)". Urologia Journal 59, n.º 1_suppl (enero de 1992): 48–50. http://dx.doi.org/10.1177/039156039205901s15.
Texto completoZattoni, F. "Benign Prostatic Hypertrophy, Prostatic Cancer and Preneoplastic Lesions". Urologia Journal 59, n.º 1 (febrero de 1992): 58–60. http://dx.doi.org/10.1177/039156039205900113.
Texto completoKuriyama, Manabu. "Prostate-Specific Antigen in Prostate Cancer". International Journal of Biological Markers 1, n.º 2 (mayo de 1986): 67–76. http://dx.doi.org/10.1177/172460088600100202.
Texto completoTesis sobre el tema "Prostate – Hypertrophy"
Chang, Ching-Jey George. "Prostate, benign hypertrophy and prostatic carcinoma - a study of cell biology of prostate and chemotherapy for prostatic hypertrophy and prostatic cancer /". The Ohio State University, 1994. http://rave.ohiolink.edu/etdc/view?acc_num=osu1487856906256116.
Texto completoHerrera, Maria Lourdes C. "The expression of various growth factors in the normal human prostate, benign prostatic hyperplasia, and prostate carcinoma". Thesis, Hong Kong : University of Hong Kong, 1996. http://sunzi.lib.hku.hk/hkuto/record.jsp?B1754628X.
Texto completoViennois, Emilie. "Impact d'une invalidation de LXRα sur la physiologie prostatique : un dialogue avec la signalisation androgénique". Phd thesis, Université Blaise Pascal - Clermont-Ferrand II, 2011. http://tel.archives-ouvertes.fr/tel-00841380.
Texto completoAmbrosini, Gina L. "Dietary risk factors for prostate cancer and benign prostatic hyperplasia". University of Western Australia. School of Population Health, 2008. http://theses.library.uwa.edu.au/adt-WU2008.0135.
Texto completoSmith, Carolyn Margaret. "Characterisation of androgen metabolism and 5α-reductase activity in human prostate cells in vitro". Thesis, University College London (University of London), 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.308889.
Texto completoLima, Junior Mario Maciel de 1974. "Analise do perfil genotipico do sistema glutationa S-transferase e citocromo P450 na avaliação de susceptibilidade ao cancer de prostata e de prognostico". [s.n.], 2006. http://repositorio.unicamp.br/jspui/handle/REPOSIP/310275.
Texto completoDissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas
Made available in DSpace on 2018-08-06T20:05:49Z (GMT). No. of bitstreams: 1 LimaJunior_MarioMacielde_M.pdf: 2114915 bytes, checksum: 56c9d6904dd7e0a16ab5565b0d280b7c (MD5) Previous issue date: 2006
Resumo: O câncer de próstata (CaP) é atualmente a neoplasia maligna mais prevalente no mundo, após os tumores de pele. A incidência dessa enfermidade tem crescido nas últimas décadas devido, principalmente; ao aumento da longevidade da população. Atualmente o CaP tem sido detectado em estágios menos avançados do que no passado. As melhorias dos métodos de diagnóstico contribuem para a detecção precoce dessa neoplasia. Os polimorfismos de genes que codificam enzimas envolvidas na metabolização de drogas e de xenobióticos, como as do sistema Glutationa S-transferase (GST) e Citocromo P450 (CYP), podem estar implicados no risco e prognóstico para neoplasias. Foram avaliados os genótipos de GSTT1, GSTM1, GSTP1, GSTO1 e CYP1A1 em 125 pacientes portadores de câncer de próstata e em 100 indivíduos com hiperplasia prostática benigna. Tempo e atividade ocupacional, tabagismo e outros dados relevantes da história natural da doença foram obtidas por meio de entrevistas. Não foram encontrados quaisquer associações entre os genótipos estudados e o risco de câncer de próstata, tanto avaliando os diferentes genótipos em separado como em combinações, através de análise de regressão logística uni ou multivariada. Não houve associação entre os genótipos estudados e fatores clínicos de risco para câncer de próstata ou quaisquer parâmetros de agressividade do tumor ao diagnóstico ou durante o seguimento. Nossos dados permitem concluir que os genótipos de GST e CYP1A1 não estão associados à susceptibilidade ao câncer de próstata ou à sua evolução na população brasileira estudada
Abstract: Prostate cancer is currently the most common malignancy worldwide, second only to skin tumors. The incidence of prostate cancer has risen dramatically over the last decade, more than can be explained just by the increase in longevity. It is also apparent that prostate cancer is now being detected at less advanced stages than in the past. Increased awareness of the disease and improved detection methods are thought to contribute to this earlier detection. The polymorphic inheritance of human drug-metabolizing enzymes, such as those encoded by the Glutathione-S-Transferase (GST) and the Cytochrome P450 (CYP) systems, may be implicated in both cancer risk and prognostic. We compared GSTT1, GSTM1, GSTO1, GSTP1 e CYP1A1 genotypes of 125 prostate cancer and 100 benign prostatic hyperplasia patients. Lifetime occupational history, cigarette-smoking, and other anamnestic data were obtained through interviews. None of the studied polymorphisms was found associated to prostate cancer risk either considered in separate or in combination, in uni ou multivariate regression logistic analysis. Also, there was no association between genotypes and possible clinical factors of risk, or any parameter of tumor agressiveness at diagnosis or during follow-up. Our data suggest that GST and CYP1A1 genotypes are not associated to the susceptibility to prostate cancer or its outcome in the Brazilian population
Mestrado
Clinica Medica
Mestre em Clinica Medica
Tsang, K. K. "Screening for benign prostatic hypertrophy". Thesis, University of Edinburgh, 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.663068.
Texto completoCOEURDACIER, PIERRE. "Resultats a long terme de la chirurgie pour hypertrophie benigne de prostate". Rennes 1, 1993. http://www.theses.fr/1993REN1M027.
Texto completoAhouandjinou, Theodora Vignon. "Facteurs nutritionnels associés à la présence de lésions précancéreuses de la prostate (PIN) chez des hommes ayant une hypertrophie bénigne de la protestate". Master's thesis, Université Laval, 2008. http://hdl.handle.net/20.500.11794/19946.
Texto completoDUCHEMIN, JEAN-MICHEL. "Place de l'adenomectomie retro-pubienne dans le traitement chirurgical de l'hypertrophie benigne de la prostate". Amiens, 1994. http://www.theses.fr/1994AMIEM090.
Texto completoLibros sobre el tema "Prostate – Hypertrophy"
Ayurvedic managment of benign prostate hypertrophy. Colombo, Sri Lanka: S. Godage & Brothers (Pvt) Ltd., 2014.
Buscar texto completo1952-, Norman Richard W., Canadian Medical Association y Canadian Prostate Health Council, eds. A prostate problem: Benign prostatic hyperplasia : a physician's guide to care and counselling. Montréal: Grosvenor House Press, 1993.
Buscar texto completoCunningham, Chet. Your prostate: What every man over 40 needs to know....NOW! 2a ed. Leucadia, Calif: United Research Publishers, 1992.
Buscar texto completoChet, Cunningham y Chet Cunningham. Your prostate: What every man over 40 needs to know-- now! Leucadia, Calif: United Research Publishers, 1990.
Buscar texto completoKathleen, Doheny, ed. The well-informed patient's guide to prostate problems. New York: Dell, 1993.
Buscar texto completoH, Schröder F., ed. Recent advances in prostate cancer and BPH: The proceedings of the IV Congress on Progress and Controversies in Oncological Urology (PACIOU IV), held in Rotterdam, the Netherlands, April 1996. New York: Parthenon, 1997.
Buscar texto completoKyoichi, Imai, Shimazaki Jun y Karr James P, eds. Fundamental approaches to the diagnosis & treatment for prostate cancer and BPH: Proceedings of the Fifth Tokyo Symposium on Prostate Cancer, December 16-17, 1993, Keidanren-Kaikan, Tokyo, Japan. Schenectady, NY, USA: Adenine Press, 1994.
Buscar texto completoHonma, Yukio. Subete wakaru!! zenritsusen gan, hidaishō. Tōkyō: Mainichi Shinbunsha, 2005.
Buscar texto completoShe hu xian fei da. Taibei Xian Shenkeng Xiang: Yuan lu shu she, 2010.
Buscar texto completoParker, Philip M. y James N. Parker. Enlarged prostate: A medical dictionary, bibliography, and annotated research guide to Internet references. San Diego, CA: ICON Health Publications, 2004.
Buscar texto completoCapítulos de libros sobre el tema "Prostate – Hypertrophy"
Order, Stanley E. y Sarah S. Donaldson. "Benign Prostate Hypertrophy". En Radiation Therapy of Benign Diseases, 44. Berlin, Heidelberg: Springer Berlin Heidelberg, 2003. http://dx.doi.org/10.1007/978-3-642-58719-1_23.
Texto completoHoffman, Robert M. "Clinical Usefulness of the Histoculture Drug Response Assay for Prostate Cancer and Benign Prostate Hypertrophy (BPH)". En 3D Sponge-Matrix Histoculture, 101–7. New York, NY: Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4939-7745-1_11.
Texto completoScattoni, Vincenzo y Carmen Maccagnano. "Benign Prostatic Hypertrophy". En Atlas of Ultrasonography in Urology, Andrology, and Nephrology, 281–91. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-40782-1_23.
Texto completoMebust, W. K. "Benign Prostatic Hypertrophy: Standards and Guidelines". En Alternate Methods in the Treatment of Benign Prostatic Hyperplasia, 26–44. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-45723-4_3.
Texto completoSullivan, M. P. y S. V. Yalla. "Urodynamic Assessment of Benign Prostatic Hypertrophy". En Alternate Methods in the Treatment of Benign Prostatic Hyperplasia, 66–89. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-45723-4_5.
Texto completoStone, N. N. "Flutamide and Aromatase Inhibitors in Benign Prostatic Hypertrophy". En Alternate Methods in the Treatment of Benign Prostatic Hyperplasia, 183–93. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-45723-4_12.
Texto completoLomas, Derek J. y Amy Krambeck. "Surgical management of lower urinary tract symptoms secondary to benign prostatic hypertrophy". En Evidence-Based Urology, 527–37. Chichester, UK: John Wiley & Sons, Ltd, 2018. http://dx.doi.org/10.1002/9781119129875.ch46.
Texto completoSimon, Chantal, Hazel Everitt, Françoise van Dorp y Matt Burkes. "Renal medicine and urology". En Oxford Handbook of General Practice, 435–70. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199671038.003.0014.
Texto completoShaw, Aidan, Irfan Ahmed y Tarun Sabharwal. "Prostate artery embolization for benign prostate hypertrophy". En Challenging Concepts in Interventional Radiology and Endovascular Procedures, 195–200. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199664382.003.0023.
Texto completo"PROSTATIC HYPERTROPHY AND CANCER OF THE PROSTATE". En General Practice for Lawyers, 209–16. Routledge-Cavendish, 1996. http://dx.doi.org/10.4324/9781843143604-24.
Texto completoActas de conferencias sobre el tema "Prostate – Hypertrophy"
Gomella, Leonard G., M. A. Lotfi, Douglas F. Milam, David Albala y Gary Reagan. "Contact laser vaporization of the prostate for benign prostatic hypertrophy". En OE/LASE '94, editado por Graham M. Watson, Rudolf W. Steiner y Douglas E. Johnson. SPIE, 1994. http://dx.doi.org/10.1117/12.175023.
Texto completoWalendziuk, Wojciech, Aleksander Sawicki y Adam Idźkowski. "The supporting method for automatic diagnosis of prostatic hypertrophy". En Biomdlore. VGTU Technika, 2016. http://dx.doi.org/10.3846/biomdlore.2016.13.
Texto completoMuschter, Rolf, Alfons G. Hofstetter, Stefan F. F. Hessel, Ernst Keiditsch, Karl-Heinz Rothenberger, Peter Schneede y Klaus H. Frank. "Hi-tech of the prostate: interstitial laser coagulation of benign prostatic hypertrophy". En OE/LASE '92, editado por R. R. Anderson. SPIE, 1992. http://dx.doi.org/10.1117/12.137385.
Texto completoWu, Jianchun y David L. Crowe. "Abstract 1464: Telomere DNA damage links benign prostatic hypertrophy, intraepithelial neoplasia, and prostate cancer". En Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-1464.
Texto completoTanaka, Mami, Mitsuyuki Furubayashi, Yoshikatsu Tanahashi y Seiji Chonan. "Active palpation sensor for detecting prostatic cancer and hypertrophy". En Smart Materials and MEMS, editado por Dinesh K. Sood, Ronald A. Lawes y Vasundara V. Varadan. SPIE, 2001. http://dx.doi.org/10.1117/12.420885.
Texto completo